Your browser doesn't support javascript.
loading
Brain function in classic galactosemia, a galactosemia network (GalNet) members review.
Panis, Bianca; Vos, E Naomi; Baric, Ivo; Bosch, Annet M; Brouwers, Martijn C G J; Burlina, Alberto; Cassiman, David; Coman, David J; Couce, María L; Das, Anibh M; Demirbas, Didem; Empain, Aurélie; Gautschi, Matthias; Grafakou, Olga; Grunewald, Stephanie; Kingma, Sandra D K; Knerr, Ina; Leão-Teles, Elisa; Möslinger, Dorothea; Murphy, Elaine; Õunap, Katrin; Pané, Adriana; Paci, Sabrina; Parini, Rossella; Rivera, Isabel A; Scholl-Bürgi, Sabine; Schwartz, Ida V D; Sdogou, Triantafyllia; Shakerdi, Loai A; Skouma, Anastasia; Stepien, Karolina M; Treacy, Eileen P; Waisbren, Susan; Berry, Gerard T; Rubio-Gozalbo, M Estela.
Afiliação
  • Panis B; Department of Pediatrics, MosaKids Children's Hospital, Maastricht University Medical Centre, Maastricht, Netherlands.
  • Vos EN; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Baric I; United for Metabolic Diseases (UMD), Amsterdam, Netherlands.
  • Bosch AM; Department of Pediatrics, MosaKids Children's Hospital, Maastricht University Medical Centre, Maastricht, Netherlands.
  • Brouwers MCGJ; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Burlina A; United for Metabolic Diseases (UMD), Amsterdam, Netherlands.
  • Cassiman D; Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
  • Coman DJ; GROW School for Oncology and Reproduction, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.
  • Couce ML; Department of Pediatrics, University Hospital Center Zagreb, Croatia, and School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Das AM; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Demirbas D; United for Metabolic Diseases (UMD), Amsterdam, Netherlands.
  • Empain A; Department of Pediatrics, Division of Metabolic Diseases, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam Gastroenterology Endocrinology Metabolism, Inborn Errors of Metabolism, Amsterdam, Netherlands.
  • Gautschi M; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Grafakou O; Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands.
  • Grunewald S; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Kingma SDK; Division of Inherited Metabolic Diseases, Reference Centre Expanded Newborn Screening, University Hospital Padova, Padova, Italy.
  • Knerr I; Laboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, Faculty of Medicine, KU Leuven, Leuven, Belgium.
  • Leão-Teles E; Queensland Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia.
  • Möslinger D; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Murphy E; Department of Pediatrics, Diagnosis and Treatment Unit of Congenital Metabolic Diseases, University Clinical Hospital of Santiago de Compostela, IDIS-Health Research Institute of Santiago de Compostela, CIBERER, RICORS Instituto Salud Carlos III, Santiago de Compostela, Spain.
  • Õunap K; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Pané A; Department of Paediatrics, Pediatric Metabolic Medicine, Hannover Medical School, Hannover, Germany.
  • Paci S; Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Manton Center for Orphan Disease Research, Boston, MA, United States.
  • Parini R; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Rivera IA; Department of Paediatrics, Metabolic and Nutrition Unit, Division of Endocrinology, Diabetes and Metabolism, University Hospital for Children Queen Fabiola, Bruxelles, Belgium.
  • Scholl-Bürgi S; Department of Paediatrics, Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Swiss Reference Centre for Inborn Errors of Metabolism, Site Bern, Division of Pediatric Endocrinology, Diabetes and Metabolism, University of Bern, Bern, Switzerland.
  • Schwartz IVD; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Sdogou T; IEM Clinic, Arch Makarios III Hospital, Nicosia, Cyprus.
  • Shakerdi LA; Metabolic Unit Great Ormond Street Hospital and Institute for Child Health, University College London, London, United Kingdom.
  • Skouma A; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Stepien KM; Centre for Metabolic Diseases, University Hospital Antwerp, University of Antwerp, Antwerp, Belgium.
  • Treacy EP; National Centre for Inherited Metabolic Disorders, Children's Health Ireland at Temple Street, University College Dublin, Dublin, Ireland.
  • Waisbren S; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
  • Berry GT; Reference Centre of Inherited Metabolic Diseases, Centro Hospitalar Universitário São João, Porto, Portugal.
  • Rubio-Gozalbo ME; European Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Front Genet ; 15: 1355962, 2024.
Article em En | MEDLINE | ID: mdl-38425716
ABSTRACT
Classic galactosemia (CG, OMIM #230400, ORPHA 79,239) is a hereditary disorder of galactose metabolism that, despite treatment with galactose restriction, affects brain function in 85% of the patients. Problems with cognitive function, neuropsychological/social emotional difficulties, neurological symptoms, and abnormalities in neuroimaging and electrophysiological assessments are frequently reported in this group of patients, with an enormous individual variability. In this review, we describe the role of impaired galactose metabolism on brain dysfunction based on state of the art knowledge. Several proposed disease mechanisms are discussed, as well as the time of damage and potential treatment options. Furthermore, we combine data from longitudinal, cross-sectional and retrospective studies with the observations of specialist teams treating this disease to depict the brain disease course over time. Based on current data and insights, the majority of patients do not exhibit cognitive decline. A subset of patients, often with early onset cerebral and cerebellar volume loss, can nevertheless experience neurological worsening. While a large number of patients with CG suffer from anxiety and depression, the increased complaints about memory loss, anxiety and depression at an older age are likely multifactorial in origin.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Genet Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Genet Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda
...